Related Experiment Video
Updated: Aug 2, 2026

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
Published on: October 2, 2016
Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA)
J C Kraner1, D J McCoy, M A Evans
1AIT Laboratories, Indianapolis, Indiana 46241, USA.
Abstract:
The past several years have seen a marked increase in the recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "Ecstasy". MDMA use is especially common among young people participating in dance parties called "raves". Paramethoxyamphetamine (PMA) exhibits both structural and pharmacological similarity to MDMA. It may, however, be a more potent central stimulant, particularly in its effects on serotonergic transmission. Several fatalities from PMA have been reported in Australia, and here we report three recent fatalities that occurred in the midwestern United States in which each of the decedents believed that they were ingesting MDMA. Symptoms observed included agitation and bruxism, progressing to severe hyperthermia, convulsions, and hemorrhage. Blood was screened for drugs of abuse by enzyme immunoassay with the presence of amphetamines indicated in each case. Confirmation and quantitation for amphetamines was performed by gas chromatography-mass spectrometry. The deceased, two males ages 19 and 24 and a female age 18, had postmortem blood PMA concentrations of 1.07, 0.60, and 1.90 mg/L, respectively. PMA is not a contaminant of MDMA, and no MDMA was found in any of these cases. The primary metabolite of PMA is produced by O-demethylation to 4-hydroxyamphetamine, a reaction catalyzed by cytochrome P450 2D6. This enzyme is noted to be genetically polymorphic. Those with the "slow metabolizer" phenotype may be likely to have higher peak blood concentrations of PMA. Whether any of the decedents described herein were of the slow metabolizer phenotype is not known. Several groups have advocated the onsite use of the Marquis Test for the purpose of pill screening in efforts to distinguish PMA from MDMA. A dark purple is consistent with MDMA, whereas PMA imparts no color change in this test. PMA is often in the form of a white pill with a Mitsubishi symbol on one side. This design has been identified in at least one of these fatalities.
Insights
Paramethoxyamphetamine (PMA) caused three fatalities in the US, with individuals mistaking it for MDMA (Ecstasy). PMA is a potent stimulant, and its presence highlights the dangers of recreational drug use.
Area of Science:
- Forensic Toxicology
- Pharmacology
- Public Health
Background:
- Recreational use of 3,4-methylenedioxymethamphetamine (MDMA), or Ecstasy, has increased, particularly at rave events.
- Paramethoxyamphetamine (PMA) shares structural and pharmacological similarities with MDMA but may be a more potent stimulant.
- Fatalities attributed to PMA have been reported, necessitating further investigation into its toxicity and prevalence.
Observation:
- Three recent fatalities in the midwestern United States involved individuals who believed they were ingesting MDMA.
- Autopsies revealed severe hyperthermia, convulsions, and hemorrhage as symptoms.
- Postmortem blood analysis confirmed the presence of PMA at concentrations ranging from 0.60 to 1.90 mg/L, with no detectable MDMA.
Findings:
- Gas chromatography-mass spectrometry confirmed PMA as the sole amphetamine detected in the deceased.
- PMA is not a contaminant of MDMA; these cases involved pure PMA ingestion.
- The metabolism of PMA involves cytochrome P450 2D6, an enzyme known for genetic polymorphism, potentially affecting individual susceptibility.
Implications:
- This study underscores the critical danger of misidentifying PMA as MDMA due to potentially fatal outcomes.
- Onsite pill screening tests, like the Marquis Test, can help differentiate PMA from MDMA.
- Awareness of PMA's distinct pill appearance (e.g., white with a Mitsubishi symbol) is crucial for harm reduction efforts.
Related Concept Videos
Physical Properties of Amines
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
CNS Stimulants: Psychedelic Agents
Toxidromes: Clinical Features
Pharmaceutical Poisoning: Potential Scenarios
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...

